Literature DB >> 27634305

Is Modern Medical Management Changing Ultimate Patient Outcomes in Inflammatory Bowel Disease?

Quinton M Hatch1, Rubina Ratnaparkhi2, Alison Althans2, Michael Keating2, Ruel Neupane2, Madhuri Nishtala2, Eric K Johnson3, Scott R Steele2.   

Abstract

BACKGROUND: The impact of modern medical management of inflammatory bowel disease (IBD) on surgical necessity and outcomes remains unclear. We hypothesized that surgery rates have decreased while outcomes have worsened due to operating on "sicker" patients since the introduction of biologic medications.
METHODS: The Nationwide Inpatient Sample and ICD-9-CM codes were used to identify inpatient admissions for Crohn's disease and ulcerative colitis. Trends in IBD nutrition, surgeries, and postoperative complications were determined.
RESULTS: There were 191,743 admissions for IBD during the study period. Surgery rates were largely unchanged over the study period, ranging from 9 to 12 % of admissions in both Crohn's disease and ulcerative colitis. The rate of poor nutrition increased by 67 % in ulcerative colitis and by 83 % in Crohn's disease. Rates of postoperative anastomotic leak (10.2-13.9 %) were unchanged over the years. Postoperative infection rates decreased by 17 % in Crohn's disease (18 % in 2003 to 15 % in 2012; P < 0.001) but did not show a trend in any direction in ulcerative colitis.
CONCLUSIONS: Rates of IBD surgery have remained stable while postoperative infectious complications have remained stable or decreased since the implementation of biologic therapies. We identified an increase in poor nutrition in surgical patients.

Entities:  

Keywords:  Crohn’s disease; Inflammatory bowel disease; Surgery; Ulcerative colitis

Mesh:

Year:  2016        PMID: 27634305     DOI: 10.1007/s11605-016-3275-z

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  24 in total

1.  The effects of infliximab maintenance therapy on health-related quality of life.

Authors:  Brian G Feagan; Songkai Yan; Mohan Bala; Weihang Bao; Gary R Lichtenstein
Journal:  Am J Gastroenterol       Date:  2003-10       Impact factor: 10.864

2.  The impact of obesity on outcomes following major surgery for Crohn's disease: an American College of Surgeons National Surgical Quality Improvement Program assessment.

Authors:  Marlin W Causey; Eric K Johnson; Seth Miller; Matthew Martin; Justin Maykel; Scott R Steele
Journal:  Dis Colon Rectum       Date:  2011-12       Impact factor: 4.585

3.  Effects of enteral nutritional support on malnourished patients with inflammatory bowel disease by subjective global assessment.

Authors:  Pınar Sökülmez; Ali Eba Demirbağ; Perihan Arslan; Selçuk Dişibeyaz
Journal:  Turk J Gastroenterol       Date:  2014-10       Impact factor: 1.852

4.  Infliximab for induction and maintenance therapy for ulcerative colitis.

Authors:  Paul Rutgeerts; William J Sandborn; Brian G Feagan; Walter Reinisch; Allan Olson; Jewel Johanns; Suzanne Travers; Daniel Rachmilewitz; Stephen B Hanauer; Gary R Lichtenstein; Willem J S de Villiers; Daniel Present; Bruce E Sands; Jean Frédéric Colombel
Journal:  N Engl J Med       Date:  2005-12-08       Impact factor: 91.245

5.  Initial surgical management of ulcerative colitis in the biologic era.

Authors:  Cristina B Geltzeiler; Kim C Lu; Brian S Diggs; Karen E Deveney; Kian Keyashian; Daniel O Herzig; Vassiliki L Tsikitis
Journal:  Dis Colon Rectum       Date:  2014-12       Impact factor: 4.585

6.  Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Authors:  Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

7.  Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab.

Authors:  William J Sandborn; Paul Rutgeerts; Brian G Feagan; Walter Reinisch; Allan Olson; Jewel Johanns; Jiandong Lu; Kevin Horgan; Daniel Rachmilewitz; Stephen B Hanauer; Gary R Lichtenstein; Willem J S de Villiers; Daniel Present; Bruce E Sands; Jean Frédéric Colombel
Journal:  Gastroenterology       Date:  2009-07-28       Impact factor: 22.682

8.  Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn's patients.

Authors:  Kweku A Appau; Victor W Fazio; Bo Shen; James M Church; Bret Lashner; Feza Remzi; Aaron Brzezinski; Scott A Strong; Jeffrey Hammel; Ravi P Kiran
Journal:  J Gastrointest Surg       Date:  2008-08-15       Impact factor: 3.452

9.  Meta-analysis: effect of preoperative infliximab use on early postoperative complications in patients with ulcerative colitis undergoing abdominal surgery.

Authors:  Z Yang; Q Wu; F Wang; K Wu; D Fan
Journal:  Aliment Pharmacol Ther       Date:  2012-09-24       Impact factor: 8.171

Review 10.  Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.

Authors:  B W Behm; S J Bickston
Journal:  Cochrane Database Syst Rev       Date:  2008-01-23
View more
  4 in total

1.  Declining Rates of Surgery for Inflammatory Bowel Disease in the Era of Biologic Therapy.

Authors:  Sarina C Lowe; Jenny S Sauk; Berkeley N Limketkai; Mary R Kwaan
Journal:  J Gastrointest Surg       Date:  2020-11-02       Impact factor: 3.452

2.  Increased Risk of Infections with Anti-TNF Agents in Patients with Crohn's Disease After Elective Surgery: Meta-Analysis.

Authors:  Jurij Hanzel; Ahmed Almradi; Alexandra C Istl; Mei Lucy Yang; Katherine A Fleshner; Claire E Parker; Leonardo Guizzetti; Christopher Ma; Siddharth Singh; Vipul Jairath
Journal:  Dig Dis Sci       Date:  2021-02-26       Impact factor: 3.199

Review 3.  Surgery in Pediatric Crohn's Disease: Indications, Timing and Post-Operative Management.

Authors:  Seung Kim
Journal:  Pediatr Gastroenterol Hepatol Nutr       Date:  2017-03-27

4.  Changing nationwide trends in endoscopic, medical and surgical admissions for inflammatory bowel disease: 2003-2013.

Authors:  Ahmir Ahmad; Anthony A Laverty; Chris Alexakis; Tom Cowling; Sonia Saxena; Azeem Majeed; Richard C G Pollok
Journal:  BMJ Open Gastroenterol       Date:  2018-03-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.